L-Carnitine (10mg & 10ml)

L-Carnitine (500 mg / 10 ml): Levocarnitine — A Highly Polar Small Zwitterion and Essential Cofactor of Mitochondrial β-Oxidation, with the Chemical Name (3R)-3-Hydroxy-4-(trimethylazaniumyl)butanoate, CAS Number 541-15-1, Molecular Formula C7H15NO3, Molecular Weight 161.20 g/mol, That Functions as the Indispensable Carrier for Transporting Long-Chain Fatty Acids (C12–C18) from the Cytosol into the Mitochondrial Matrix for β-Oxidation and ATP Generation — Through the Coordinated Carnitine Shuttle System Involving Carnitine Palmitoyltransferase I (CPT1, on the Outer Mitochondrial Membrane, the Rate-Limiting Step Regulated by Malonyl-CoA), Carnitine-Acylcarnitine Translocase (CACT, on the Inner Mitochondrial Membrane), and Carnitine Palmitoyltransferase II (CPT2, in the Mitochondrial Matrix) — With Additional Pleiotropic Effects Including Antioxidant Activity, Cell Membrane Protection, Prevention of Fatty Acid Accumulation, Modulation of Ketogenesis and Gluconeogenesis, Elimination of Toxic Metabolites, Acetyl Group Buffering (via Acetyl-L-Carnitine), and the Ability to Cross the Blood-Brain Barrier to Support Cerebral Energy Metabolism — With Extensive Clinical Evidence Supporting Its Use in Primary and Secondary Carnitine Deficiency, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD/NASH), Exercise Recovery, Chronic Kidney Disease-Associated Carnitine Deficiency, Preterm Infant Management, and Male Infertility (Where Network Meta-Analyses of 23 RCTs Involving 1,917 Patients and 10 Antioxidants Demonstrate That L-Carnitine Produces the Most Significant Improvements in Sperm Motility and Morphology, with Mean Difference = 12.43, 95% CI 4.07–20.26) — Generally Well-Tolerated with Mild Side Effects Including Gastrointestinal Disturbances and Fishy Body Odor at High Doses

L-Carnitine — also known by the generic name levocarnitine, the chemical name (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate, CAS number 541-15-1, molecular formula C7H15NO3, and molecular weight 161.20 g/mol — is a highly polar small zwitterion that serves as an essential cofactor of mitochondrial β-oxidation, the metabolic pathway by which long-chain fatty acids are broken down to generate energy in the form of adenosine triphosphate (ATP). L-Carnitine was first identified in 1905 by Russian scientists V.S. Gulewitsch and R. Krimberg in muscle extract (from the Latin "carnis" meaning flesh, reflecting its high concentration in skeletal muscle), and its essential role in fatty acid oxidation was elucidated in the 1950s by Fritz and colleagues. The human body can synthesize L-carnitine endogenously in the liver, kidneys, and brain from the amino acids lysine and methionine, in a process requiring vitamin C, iron, vitamin B6, and niacin as cofactors — but endogenous synthesis is often insufficient to meet metabolic demands, making dietary intake (primarily from red meat, dairy products, and fish) and/or supplementation important for maintaining adequate tissue levels. L-Carnitine is classified as a "conditionally essential" nutrient — meaning that under certain conditions (such as prematurity, genetic defects in carnitine transport or synthesis, chronic kidney disease, liver disease, certain medications, or increased metabolic demand), endogenous synthesis and dietary intake may be inadequate to maintain normal carnitine homeostasis, necessitating exogenous supplementation. The fundamental and best-characterized function of L-carnitine is its role as the indispensable carrier for transporting long-chain fatty acids (C12–C18 chain length) from the cytosol, where they are activated to acyl-CoA esters, across the otherwise impermeable inner mitochondrial membrane into the mitochondrial matrix, where β-oxidation occurs — this transport is accomplished through the coordinated "carnitine shuttle system" involving three key proteins: carnitine palmitoyltransferase I (CPT1, located on the outer mitochondrial membrane, which catalyzes the transfer of the acyl group from acyl-CoA to carnitine to form acyl-carnitine, and which is the rate-limiting step of the shuttle, regulated allosterically by malonyl-CoA as a sensor of nutritional state), carnitine-acylcarnitine translocase (CACT, located on the inner mitochondrial membrane, which catalyzes the electroneutral exchange of acyl-carnitine into the matrix for free carnitine out of the matrix), and carnitine palmitoyltransferase II (CPT2, located on the inner face of the inner mitochondrial membrane in the matrix, which reconverts acyl-carnitine back to acyl-CoA and free carnitine, making the acyl-CoA available for β-oxidation). Beyond its canonical role in fatty acid transport and energy metabolism, L-carnitine exerts a wide range of additional pleiotropic effects: it acts as an antioxidant by scavenging reactive oxygen species (ROS) and chelating iron and copper ions; it protects cell membranes from peroxidative damage; it prevents the toxic accumulation of fatty acids and acyl-CoA esters in the cytosol; it modulates ketogenesis and gluconeogenesis; it facilitates the elimination of toxic acyl metabolites (by conjugating them to carnitine for urinary excretion, as seen in organic acidurias); it serves as an acetyl group buffer (through its esterified form acetyl-L-carnitine, which can donate or accept acetyl groups to maintain acetyl-CoA homeostasis); and it can traverse the blood-brain barrier to directly support cerebral energy metabolism and function — a property of particular relevance for brain health, given the brain's substantial energy requirements and its ability to utilize ketone bodies (derived from fatty acid oxidation) as an alternative fuel source. L-Carnitine is available in several forms, including L-carnitine (the free, biologically active form), acetyl-L-carnitine (ALCAR, the acetylated form with enhanced blood-brain barrier penetration and neurotrophic properties), L-carnitine L-tartrate (LCLT, a salt form with enhanced bioavailability commonly used for exercise recovery), and propionyl-L-carnitine (PLC, the propionylated form with particular cardiovascular and peripheral vascular benefits). The product offered here is L-Carnitine 500 mg / 10 ml oral solution, intended for dietary supplementation and clinical use under medical supervision^{[1][2][3][4][5][6][7][8][9][10][11][12]}.

Mechanism of Action: The Carnitine Shuttle System — Mitochondrial Fatty Acid Transport and β-Oxidation

The canonical mechanism of action of L-carnitine centers on the carnitine shuttle system — the coordinated enzymatic transport pathway that moves long-chain fatty acids from the cytosol into the mitochondrial matrix for β-oxidation and ATP generation. This pathway is essential because long-chain fatty acyl-CoA esters cannot freely diffuse across the inner mitochondrial membrane (which is impermeable to CoA and its thioesters), and because β-oxidation enzymes are located exclusively in the mitochondrial matrix. The carnitine shuttle proceeds in five coordinated steps, illustrated in the mechanism diagram below^{[1][2][3][4][5][6]}:

Step 1 — Activation in the cytosol: Long-chain fatty acids (C12–C18 chain length) cannot directly enter β-oxidation; they must first be activated in the cytosol by acyl-CoA synthetase enzymes (also called fatty acid thiokinases), which catalyze the ATP-dependent esterification of the fatty acid with coenzyme A (CoA) to form a long-chain acyl-CoA ester. This activation occurs on the outer mitochondrial membrane and endoplasmic reticulum, and it is essential because the β-oxidation enzymes recognize only acyl-CoA esters, not free fatty acids. However, the resulting acyl-CoA ester is too large and polar to cross the inner mitochondrial membrane — which is impermeable to CoA and its thioesters — so a specialized transport system is required to move the acyl group into the matrix^{[1][2][3][4][5][6]}.

Step 2 — CPT1 (carnitine palmitoyltransferase I) on the outer mitochondrial membrane: CPT1 — also called carnitine palmitoyltransferase 1A (liver isoform, CPT1A), 1B (muscle isoform, CPT1B), or 1C (brain isoform, CPT1C), with tissue-specific expression — is the key regulatory enzyme of the carnitine shuttle and the rate-limiting step in long-chain fatty acid oxidation. CPT1 is an integral protein of the outer mitochondrial membrane that catalyzes the reversible transfer of the acyl group from acyl-CoA to L-carnitine, forming acyl-carnitine and releasing free CoA in the cytosol. CPT1 is allosterically inhibited by malonyl-CoA — the first committed intermediate in fatty acid synthesis (lipogenesis) — which serves as the critical molecular link between nutritional state and fatty acid oxidation: in the fed state, high glucose and insulin activate acetyl-CoA carboxylase (ACC), increasing malonyl-CoA levels, which inhibits CPT1 and diverts fatty acids toward triglyceride synthesis rather than oxidation; in the fasted state, low glucose and high glucagon activate AMP-activated protein kinase (AMPK), which phosphorylates and inhibits ACC, reducing malonyl-CoA levels, relieving CPT1 inhibition, and allowing increased fatty acid oxidation and ketogenesis. This elegant regulatory mechanism ensures that fatty acid oxidation is coordinated with the body's energy needs and nutritional state^{[1][2][3][4][5][6]}.

Step 3 — CACT (carnitine-acylcarnitine translocase) on the inner mitochondrial membrane: Once acyl-carnitine is formed in the intermembrane space (by CPT1 on the outer membrane), it must cross the inner mitochondrial membrane — which is otherwise impermeable to acyl-carnitine and free carnitine. This transport is catalyzed by carnitine-acylcarnitine translocase (CACT, gene name SLC25A20), an integral protein of the inner mitochondrial membrane that catalyzes the electroneutral 1:1 exchange of acyl-carnitine (moving into the matrix) for free carnitine (moving out of the matrix into the intermembrane space/cytosol). This antiport mechanism ensures that the mitochondrial matrix maintains an adequate supply of free carnitine for ongoing CPT2 reactions while allowing acyl-carnitine to enter for β-oxidation. Genetic defects in CACT cause carnitine-acylcarnitine translocase deficiency — a severe, life-threatening fatty acid oxidation disorder characterized by hypoketotic hypoglycemia, hyperammonemia, cardiomyopathy, liver dysfunction, and early mortality^{[1][2][3][4][5][6]}.

Step 4 — CPT2 (carnitine palmitoyltransferase II) in the mitochondrial matrix: Once acyl-carnitine enters the mitochondrial matrix through CACT, it is reconverted back to acyl-CoA and free carnitine by carnitine palmitoyltransferase II (CPT2), an enzyme located on the inner face of the inner mitochondrial membrane (in the matrix side). CPT2 catalyzes the transfer of the acyl group from acyl-carnitine back to CoA (which is present in the matrix), regenerating long-chain acyl-CoA (now available for β-oxidation) and releasing free carnitine (which is transported back out of the matrix through CACT in exchange for more acyl-carnitine). Genetic defects in CPT2 cause CPT2 deficiency — the most common inherited disorder of mitochondrial fatty acid oxidation, with three clinical phenotypes: a lethal neonatal form, a severe infantile hepatocardiomuscular form, and a milder adult-onset myopathic form (characterized by exercise-induced muscle pain, rhabdomyolysis, and myoglobinuria, often triggered by prolonged exercise, fasting, or illness)^{[1][2][3][4][5][6]}.

Step 5 — β-oxidation in the mitochondrial matrix and ATP generation: Once long-chain acyl-CoA is regenerated in the mitochondrial matrix by CPT2, it undergoes β-oxidation — a cyclic series of four enzymatic reactions (oxidation by acyl-CoA dehydrogenase, hydration by enoyl-CoA hydratase, a second oxidation by 3-hydroxyacyl-CoA dehydrogenase, and thiolysis by β-ketothiolase) that sequentially cleave 2-carbon units from the carboxyl end of the fatty acid, producing acetyl-CoA (which enters the citric acid cycle/Krebs cycle), NADH, and FADH2 (which serve as electron donors for the electron transport chain and oxidative phosphorylation to generate ATP). Each round of β-oxidation shortens the fatty acid by 2 carbons and produces 1 acetyl-CoA, 1 NADH, and 1 FADH2; for a 16-carbon fatty acid (palmitate), this yields 8 acetyl-CoA, 7 NADH, and 7 FADH2, with a total ATP yield of approximately 106 ATP (after accounting for the 2 ATP equivalents used in the initial activation step) — making fatty acids the most energy-dense fuel source in the body (9 kcal/g vs 4 kcal/g for carbohydrates and protein). The NADH and FADH2 generated by β-oxidation and the Krebs cycle donate electrons to the electron transport chain (Complexes I-IV) on the inner mitochondrial membrane, creating a proton gradient across the inner membrane that drives ATP synthase (Complex V) to phosphorylate ADP to ATP — the universal energy currency of the cell. This entire process — from fatty acid activation in the cytosol, through the carnitine shuttle across the mitochondrial membranes, to β-oxidation, the Krebs cycle, and oxidative phosphorylation — is the fundamental pathway by which the body derives energy from fat, and L-carnitine is the indispensable carrier that makes the transport step possible^{[1][2][3][4][5][6]}.

Male Infertility Evidence — Network Meta-Analysis: A network meta-analysis of 23 randomized controlled trials involving 1,917 patients and evaluating 10 different antioxidants demonstrated that L-carnitine produced the most significant improvements in sperm motility and morphology among all antioxidants studied. In the pairwise meta-analysis, only carnitine, Coenzyme Q10, and N-acetylcysteine showed statistically significant differences (P < 0.05) compared with placebo. In the network meta-analysis, carnitine achieved a mean difference (MD) of 12.43 (95% CI: 4.07, 20.26) for sperm motility — the largest effect size among all antioxidants evaluated. A 2021 meta-analysis by Wei et al. analyzing seven articles including 621 patients confirmed that L-carnitine/L-acetyl-carnitine (LC/LAC) could result in sperm normal morphology and enhanced motility in comparison with placebo in idiopathic asthenozoospermic men. A 2021 systematic review of eight RCTs found that carnitines significantly improve total sperm motility, progressive sperm motility, and sperm morphology, but without effect on sperm concentration; however, there was no demonstrable effect on clinical pregnancy rates in the available evidence. A 2022 prospective study concluded that compared with other antioxidants, L-carnitine had the highest probability of being the most effective treatment to increase sperm motility and morphology, while omega-3 fatty acids had the most positive effect on sperm concentration and Coenzyme-Q10 was a better effective treatment for sperm motility and concentration; in terms of pregnancy rate, there was no statistical significance between treatment and placebo, and further evidence is awaited. Ma et al. (2022) found that L-carnitine enhances sperm count, morphology, and motility, in addition to increasing testosterone and LH levels. A 2020 randomized clinical trial found that the combination of L-carnitine and L-acetyl-carnitine with L-arginine, glutathione, selenium, co-enzyme Q10, zinc, folic acid, and cyanocobalamin improved sperm quality and increased fertility rates in couples with male factor infertility. It is important to note that an umbrella review of systematic reviews rated the evidence quality for L-carnitine's effect on sperm concentration as "Very low" (Wei et al. 2021, 4 studies, 190 cases, SMD 0.08, 95% CI −0.06–0.23, I²=99), reflecting the limitations of the existing evidence base — including small sample sizes, heterogeneity in formulations and dosing, variable study quality, and publication bias^{[7][8][9][10][11][12]}.

Metabolic Health, Liver Disease, and Other Clinical Applications: Beyond male infertility, L-carnitine has been studied in a wide range of clinical conditions. In metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH), L-carnitine supplementation has been shown to improve serum lipid parameters — including total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL) — in NASH patients, and high-dose carnitine orotate complex (Godex®) intervention for 6 months significantly decreased controlled attenuation parameter (CAP) values in NAFLD patients, indicating reduced hepatic steatosis; body composition analyses reveal that L-carnitine treatment reduces hepatic fat content and improves metabolic parameters. In exercise recovery, L-carnitine (particularly L-carnitine L-tartrate, LCLT) has been shown to reduce muscle damage markers, enhance recovery, and potentially improve exercise performance — particularly in endurance exercise and in individuals with reduced carnitine status. In chronic kidney disease (CKD), carnitine deficiency is common due to reduced renal synthesis, increased losses during dialysis, and impaired metabolism; L-carnitine supplementation in CKD and dialysis patients has been shown to improve carnitine levels, reduce muscle cramps, improve exercise capacity, and potentially reduce inflammation and cardiovascular risk — though evidence is mixed. In preterm infants, L-carnitine supplementation has been studied because preterm infants have immature carnitine synthesis and limited dietary intake (especially if parenterally fed); L-carnitine plays a pivotal role in meeting the brain's substantial energy requirements and can traverse the blood-brain barrier to directly support cerebral energy metabolism and function, though the clinical benefits of routine supplementation in preterm infants remain debated. In primary carnitine deficiency (a genetic disorder of the carnitine transporter OCTN2/SLC22A5), L-carnitine supplementation is life-saving and is the standard of care, preventing hypoketotic hypoglycemia, cardiomyopathy, and metabolic decompensation. In secondary carnitine deficiency (due to organic acidurias, fatty acid oxidation disorders, chronic kidney disease, liver disease, certain medications [e.g., valproic acid, zidovudine, ifosfamide], or increased metabolic demand), L-carnitine supplementation is used to restore carnitine homeostasis and prevent toxic acyl metabolite accumulation. L-carnitine also acts as an antioxidant by scavenging reactive oxygen species and chelating iron and copper ions, protects cell membranes from peroxidative damage, prevents the toxic accumulation of fatty acids and acyl-CoA esters in the cytosol, modulates ketogenesis and gluconeogenesis, and facilitates the elimination of toxic acyl metabolites (by conjugating them to carnitine for urinary excretion, as seen in organic acidurias) — these pleiotropic effects contribute to its potential therapeutic benefits across a wide range of conditions^{[1][2][3][4][5][6][7][8][9][10][11][12]}.

Safety, Side Effects, and Practical Considerations

L-Carnitine is generally well-tolerated when used at recommended doses, with a favorable safety profile supported by decades of clinical use and research. However, like any supplement or medication, it can cause side effects in some individuals, and there are important considerations regarding dosing, formulations, drug interactions, and contraindications^{[1][2][3][4][5][6][7][8][9][10][11][12]}:

Common and mild side effects: The most commonly reported side effects of L-carnitine supplementation are gastrointestinal in nature and include nausea, vomiting, diarrhea, abdominal cramps, and stomach discomfort — these are typically mild, dose-related, and can be minimized by taking L-carnitine with meals, dividing the daily dose into multiple smaller doses, or reducing the dose. A distinctive side effect at higher doses (typically >2-3 grams per day) is a fishy body odor, which results from the bacterial metabolism of unabsorbed L-carnitine in the colon to trimethylamine (TMA), which is then absorbed and oxidized in the liver to trimethylamine N-oxide (TMAO) and excreted through sweat, urine, and breath — this fishy odor can be distressing for some users but is not harmful and can be reduced by lowering the dose, using acetyl-L-carnitine (which is less prone to this effect), or ensuring adequate hydration. Other mild side effects may include insomnia or restlessness (particularly when taken late in the day, due to increased energy production), headache, muscle cramps (in some individuals, particularly at high doses), and skin rash or itching (rare, usually mild).

Rare and serious side effects: Serious side effects from L-carnitine are rare but have been reported in specific populations. In individuals with seizure disorders (epilepsy), there have been rare reports of increased seizure frequency or severity with L-carnitine supplementation — particularly with acetyl-L-carnitine — and caution is advised in this population, with monitoring by a neurologist. In individuals with peripheral vascular disease or diabetes, propionyl-L-carnitine (a specific form) may cause mild hypotension or dizziness, though this is uncommon. Allergic reactions to L-carnitine are extremely rare but can include hives, itching, swelling, and anaphylaxis in susceptible individuals. There has been some controversy regarding the potential cardiovascular risk of L-carnitine supplementation, based on studies suggesting that gut microbial metabolism of L-carnitine to TMAO may be associated with increased atherosclerosis and cardiovascular risk — however, this association remains debated, and most clinical studies have not found increased cardiovascular events with L-carnitine supplementation, particularly in healthy individuals or those without advanced kidney disease; individuals with established cardiovascular disease or chronic kidney disease should discuss L-carnitine use with their healthcare provider.

Drug interactions: L-carnitine may interact with certain medications. Antibiotics — particularly cephalosporins (e.g., cephalexin) and aminoglycosides — may increase renal excretion of carnitine, potentially reducing carnitine levels; individuals on long-term antibiotic therapy may benefit from carnitine monitoring. Anticoagulant/antiplatelet medications (e.g., warfarin, heparin, clopidogrel, aspirin) may have their effects potentiated by L-carnitine in some cases (due to L-carnitine's potential effects on platelet function and blood lipid profile), though this is not well-established; individuals on anticoagulants should have their INR/bleeding parameters monitored if starting L-carnitine. Valproic acid (an anticonvulsant and mood stabilizer) can cause secondary carnitine deficiency by increasing renal carnitine excretion and inhibiting carnitine uptake, and L-carnitine supplementation is often used therapeutically in patients on valproic acid to prevent or treat carnitine deficiency — this is a beneficial interaction, not a harmful one, but should be monitored. Certain chemotherapy agents (e.g., ifosfamide, cisplatin) can cause carnitine depletion, and L-carnitine may be used to mitigate this; ifosfamide-induced encephalopathy may be treated with L-carnitine. Thyroid hormones may interact with L-carnitine, as L-carnitine has been reported to have mild thyroid-modulating effects in some studies; individuals on thyroid medication should have their thyroid function monitored. Diabetes medications — L-carnitine may improve insulin sensitivity and glucose metabolism in some individuals with type 2 diabetes, potentially requiring adjustment of antidiabetic medication doses; blood glucose should be monitored.

Contraindications and precautions: L-carnitine is contraindicated in individuals with known hypersensitivity or allergy to L-carnitine or any of its formulations/excipients. Caution is advised in individuals with seizure disorders (epilepsy), due to rare reports of increased seizure activity. Caution is advised in individuals with chronic kidney disease or on dialysis, as carnitine metabolism and excretion are altered and dose adjustment may be necessary; L-carnitine is often used therapeutically in CKD/dialysis patients but should be monitored. Caution is advised in individuals with established cardiovascular disease, due to the theoretical TMAO-atherosclerosis association (though evidence is mixed). L-carnitine is generally considered safe in pregnancy and breastfeeding when used at recommended doses, but should be used under medical supervision; pregnant women with primary carnitine deficiency require L-carnitine supplementation to prevent maternal and fetal complications. L-carnitine is generally safe in children, including infants (it is used therapeutically in primary carnitine deficiency and organic acidurias), but dosing should be weight-based and supervised by a pediatrician or metabolic specialist. Individuals with a history of bipolar disorder or mania should use acetyl-L-carnitine with caution, as there have been rare reports of hypomania or mania induction. It is important to note that L-carnitine is a dietary supplement (in most countries) and is not intended to diagnose, treat, cure, or prevent any disease — individuals with specific medical conditions should consult a qualified healthcare provider before starting L-carnitine supplementation, particularly if they are taking medications or have underlying health conditions. The product offered here is L-Carnitine 500 mg / 10 ml oral solution, intended for dietary supplementation and clinical use under medical supervision^{[1][2][3][4][5][6][7][8][9][10][11][12]}.

References

1. The Role of L-Carnitine in Mitochondria, Prevention of Metabolic Inflexibility and Disease Initiation. PMC / International Journal of Molecular Sciences. 2022; PMC8910660. (L-carnitine = key nutrient for proper mitochondrial function, notable role in fatty acid oxidation; also major part in protecting cellular membranes, preventing fatty acid accumulation, modulating ketogenesis + glucogenesis, elimination of toxic metabolites; L-carnitine deficiency observed in many diseases including organic acidurias, inborn errors of metabolism, endocrine imbalances, liver + kidney disease; protective effects of...)
2. L-Carnitine Supplementation in Recovery after Exercise. PMC / Nutrients. 2018; PMC5872767. (Complex transported into mitochondrial matrix by carnitine palmitoyltransferase I [CPT I] + carnitine palmitoyltransferase II [CPT II]; fatty acids broken down through β-oxidation to deliver 2-carbon molecules to Krebs cycle → generation of energy as ATP; by binding acetyl group, L-carnitine can maintain...)
3. CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential. Oxford Academic / Endocrinology. 2020;161(2):bqz046. (CPT1 enzyme located on outer mitochondrial membrane, catalyzes reversible transfer of acyl-CoA groups [C12-C18 chain lengths] to L-carnitine → acyl-carnitine esters; acyl-carnitines translocated into mitochondria matrix in exchange for free carnitine — mediated by carnitine acylcarnitine translocase [CACT, gene name S...])
4. L-carnitine in metabolic dysfunction-associated steatotic liver disease: mechanisms and therapeutic potential. Frontiers in Nutrition. 2026;13:1804917. (Fatty acid metabolism encompasses long-chain, medium-chain, short-chain fatty acid processing, with carnitine playing indispensable role in long-chain fatty acid catabolism; carnitine-dependent transport system involves coordinated enzymatic reactions; long-chain fatty acids first activated to acyl-CoA esters in cytosol; CPT1 on outer mitochondrial membrane catalyzes acyl transfer from acyl-CoA to carnitine...; L-carnitine supplementation improves serum lipid parameters — total cholesterol [TC], triglycerides [TG], LDL — in NASH patients; high-dose carnitine orotate complex [Godex®] 6 months significantly decreased CAP values in NAFLD patients = reduced hepatic steatosis; body composition analyses reveal L-carnitine treatment reduces...)
5. Carnitine Deficiency in Chronic Kidney Disease: Pathophysiology, Clinical Implications, and Therapeutic Perspectives. PMC / Toxics. 2025; PMC12251438. (Acyl-CoA converted to acylcarnitine through CPT-1 [outer mitochondrial membrane]; acylcarnitine translocated across inner mitochondrial membrane by CACT + reconverted to acyl-CoA + free carnitine by CPT-II within mitochondrial matrix; regenerated acyl...; CKD carnitine deficiency due to reduced renal synthesis, increased dialysis losses, impaired metabolism)
6. L-carnitine: new perspectives on the management of preterm infants. PMC / Frontiers in Pediatrics. 2025; PMC12426001. (L-carnitine plays pivotal role in meeting brain's substantial energy requirements; acts as essential mitochondrial membrane transporter for long-chain fatty acids, facilitating their β-oxidation — major energy-yielding pathway; L-carnitine can traverse blood-brain barrier, positioning it to directly support cerebral energy metabolism + function; observational studies indicate initial carnitine uptake + serum L-carnitine...)
7. Effect of Antioxidants on Sperm Quality Parameters in Subfertile Men: Systematic Review + Network Meta-Analysis of RCTs. PMC / World Journal of Men's Health. 2022; PMC8970840. (Pairwise meta-analysis: only carnitine, CoQ10, N-acetylcysteine showed statistically significant differences [P<0.05] vs placebo; NMA: carnitine [MD = 12.43; 95% CI: 4.07, 20.26] + CoQ10 [MD = 7.33; 95%...])
8. The Effect of Antioxidants on Sperm Quality Parameters + Pregnancy Rates for Idiopathic Male Infertility: Network Meta-Analysis of RCTs. Frontiers in Endocrinology. 2022;13:810242. (Conclusion: compared with other antioxidants, L-carnitine had highest probability of being most effective treatment to increase sperm motility + morphology; ω-3 fatty acids most positive effect on sperm concentration; Coenzyme-Q10 better effective treatment for sperm motility + concentration; pregnancy rate: no statistical significance between treatment + placebo, further evidence awaited)
9. Evaluation of L-Carnitine Potential in Improvement of Male Fertility. PMC / International Journal of Reproductive BioMedicine. 2023; PMC10402461. (Meta-analysis 2021, Wei et al.: 7 articles, 621 patients, evaluated effective potential of L-carnitine/L-acetyl-carnitine [LC/LAC] in idiopathic asthenozoospermic men; results: LC/LAC could result in sperm normal morphology + enhanced motility vs placebo; study by Jihad Manssor et...; Ma et al. 2022: L-carnitine enhances sperm count, morphology, motility, + increases testosterone + LH levels; network meta-analysis 23 RCTs, 1917 patients, 10 antioxidants: L-carnitine produced most significant improvements in sperm motility + morphology)
10. A Meta-Analysis of Efficacy of L-Carnitine/L-Acetyl-Carnitine or N-Acetyl-Cysteine in Men With Idiopathic Asthenozoospermia. PMC / Frontiers in Endocrinology. 2021; PMC8108089. (Meta-analysis: PubMed, EMBASE, Cochrane Library; 7 articles, 621 patients analyzed; results: LC/LAC + NAC had considerable improvement in sperm motility...)
11. L-carnitine and L-acetylcarnitine supplementation for idiopathic male infertility. PMC / Andrology. 2021; PMC8812460. (Cochrane CENTRAL, EMBASE, MEDLINE, PubMed, ScienceDirect, Jan 2000-Apr 2020; 8 RCTs identified; analysis: carnitines significantly improve total sperm motility, progressive sperm motility, sperm morphology, but without effect on sperm concentration; no demonstrable effect on clinical...)
12. Current treatment for male infertility: an umbrella review of systematic reviews and meta-analyses. PMC / Basic and Clinical Andrology. 2024; PMC11614172. (L-carnitine — Wei et al. 2021 — RCT + non-RCT — idiopathic infertility — sperm concentration — 4 studies — 190 cases — SMD 0.08 — 95% CI −0.06–0.23 — random effects — I²=99 — GRADE: Very low quality evidence; very serious risk of bias, serious inconsistency, no serious indirectness, no serious imprecision, publication bias not detected, no plausible confounding, no magnitude of effect, no dose-response gradient; L-carnitine for sperm concentration evidence quality = Very low)
13. Dietary supplementation with novel L-carnitine multi-micronutrient in idiopathic male subfertility involving oligo-, astheno-, teratozoospermia: randomized clinical study. Wiley / Andrology. 2020. (Conclusion: findings support efficacy + safety of combination of L-carnitine + L-acetyl-carnitine with L-arginine, glutathione, selenium, co-enzyme Q10, zinc, folic acid, cyanocobalamin in improving sperm quality + increasing fertility rates in couples with male factor infertility; mechanisms of interplay between specific nutrients should be elucidated)
14. InvivoChem / Levocarnitine. InvivoChem.cn. 2026. (左旋肉碱 = highly polar small zwitterion, essential cofactor of mitochondrial β-oxidation pathway; function = transports long-chain fatty acyl-CoA into mitochondria for β-oxidation degradation; antioxidant; improves metabolic imbalance associated with many congenital metabolic defects; CAS# 541-15-1)